Candida osteomyelitis as a complication of parenteral nutrition in an infant. Successful treatment with flucytosine.
Hematogenous Candida osteomyelitis is described in a two-month-old infant, as a complication of Candida septicemia which occurred during a parenteral hyperalimentation regimen. Treatment with flucytosine led to full recovery. The scarcity of reports on hematogenous Candida osteomyelitis in infants, despite an increased incidence of Candida septicemia, and the non-specific symptomatology which the disease may assume in this age group, indicate the need for greater awareness of this complication. Flucytosine is an antifungal drug which can also be given by mouth and carries relatively low toxicity. We found flucytosine to be extremely effective in the treatment of disseminated infantile Candida osteomyelitis.
D000284:Administration, Oral; D002177:Candidiasis / Q000188:drug therapy / Q000209:etiology*; D003596:Cytosine / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005437:Flucytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007227:Infant Nutritional Physiological Phenomena; D007275:Injections, Intravenous; D008297:Male; D010019:Osteomyelitis / Q000188:drug therapy / Q000209:etiology*; D010288:Parenteral Nutrition / Q000009:adverse effects*; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*
D003596:Cytosine; D005437:Flucytosine